Capabilities
X-MAN Pathways Assays and Bespoke Isogenic Services
A wide range of optimized assays validated with control compounds are available. All data is presented in an industry standard reporting format with expert analysis from our team of cellular pharmacologists.
Assay a matched pair or panel of isogenic cell lines
Improved models of human cancer compared to over-expression systems
Condition scouting to identify correct cellular phenotype
Optimization of assay window using known agents
Screening of client compounds in a low to medium throughput
Compound Screening in Cellular Assays
A wide range of optimized assays validated with control compounds are available.
Development of bespoke assays
Target validation e.g. by siRNA
Growth Assays such as proliferation, colony forming
Signal transduction studies including cellular ELISA, Western blot
Mechanistic studies including Apoptosis, Invasion, Autophagy, Senescence
Screening of client compounds in a low to medium throughput
Hepato-, Cardio-Toxicity, isolated mitochondria studies
Tumor Microenvironment and Specialist Studies
One of the challenges that cancer researchers face in designing new cancer therapeutics is that of predicting how drug molecules will behave in the complex microenvironment that surrounds a tumor. To this end, HDS has developed a number of bespoke assays that address the complex issue of the tumor microenvironment.
Hypoxic profiling under varying oxygen concentrations
3D spheroid culture and sectioning
Low serum and nutrient studies
HTS and In-Vivo Studies
The ability to design high-throughput in-vitro and in-vivo assays based upon clinically relevant animal models that are more precise analogs of the human condition is the primary value proposition of the HDS/TD2 alliance. Using such testing strategies we can evaluate a client's compound in unique ways that predict optimal development pathways for a drug (for example determining how to best use an agent in combination with other experimental or FDA-approved treatments)
High-throughput X-MAN Pathways assays
Compound efficacy in an in-vivo setting
Target/biomarker validation
Clinical trial design/patient selection
| In partnership with: |
 |
